An update from Kyverna Therapeutics, Inc. ( (KYTX) ) is now available.
Kyverna Therapeutics announces its strategic priorities for 2025, highlighting its focus on advancing the KYV-101 CD19 CAR T-cell therapy through late-stage development and commercialization for autoimmune diseases. The company aims to achieve a first-to-market position with KYV-101 for stiff person syndrome, with a BLA filing targeted for 2026, while also expanding its pipeline with KYV-102 to enhance CAR T accessibility. The company is focusing on capital-efficient growth and has a cash runway into 2027 to support its strategic goals.
More about Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. The company’s lead product, KYV-101, is a CD19 CAR T-cell therapy candidate undergoing clinical trials for conditions like stiff person syndrome, myasthenia gravis, and lupus nephritis, leveraging its expertise in B cell-driven autoimmune diseases.
YTD Price Performance: -11.99%
Average Trading Volume: 328,934
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $148.9M
For detailed information about KYTX stock, go to TipRanks’ Stock Analysis page.